Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
Recruitment status was: Active, not recruiting
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether giving both of these drugs on the same day is more effective than giving them on different days.
PURPOSE: This randomized phase III trial is studying two different schedules of gemcitabine and oxaliplatin to compare how well they work in treating patients with metastatic pancreatic cancer.
Drug: gemcitabine hydrochloride
|Study Design:||Allocation: Randomized
Primary Purpose: Treatment
|Official Title:||Phase II Randomisee Dans Les Adenocarcinomes Metastatiques Du Pancreas: Gemox Et Gemox Simplifie. [GEMOX]|
- Objective response rate [ Designated as safety issue: No ]
- Clinical benefits and tolerability [ Designated as safety issue: Yes ]
- Progression-free and overall survival [ Designated as safety issue: No ]
|Study Start Date:||September 2004|
- Compare the objective response rate in patients with metastatic adenocarcinoma of the pancreas treated with two different schedules of gemcitabine hydrochloride and oxaliplatin.
- Compare the clinical benefits and tolerability of these regimens in these patients.
- Compare the progression-free and overall survival of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to the participating center and ECOG performance status (0 or 1 vs 2). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2.
- Arm II: Patients receive gemcitabine hydrochloride IV over 100 minutes followed by oxaliplatin IV over 2 hours on day 1.
In both arms, treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00268411
|Avignon, France, 84902|
|Beauvais, France, 60021|
|Dijon, France, 21000|
|Centre Hospitalier de Dreux|
|Dreux, France, 28100|
|Centre Hospitalier Departemental|
|La Roche Sur Yon, France, F-85025|
|Hopital Saint - Louis|
|La Rochelle, France, 17000|
|Hopital Louis Pasteur - Le Coudray|
|Le Coudray, France, 28630|
|Clinique Victor Hugo|
|Le Mans, France, F-72000|
|Polyclinique des Quatre Pavillons|
|Lormont, France, 33310|
|Clinique Saint Jean|
|Lyon, France, 69008|
|Hopital Saint Antoine|
|Paris, France, 75571|
|Paris, France, 75970|
|Centre Hospitalier Lyon Sud|
|Pierre Benite, France, 69495|
|Polyclinique De Courlancy|
|Reims, France, F-51100|
|Senlis, France, 60309|
|Study Chair:||Christophe Louvet, MD, PhD||Hopital Saint Antoine|